Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent...
Kite Pharma, Inc , a leading cell therapy company announced that patients with relapsed/refractory indolent...
Phase III Study Of Viaskin Peanut – Allergic Of Patients One To Three Years...
DBV Technologies announced that the first patient has been enrolled in EPITOPE ( EPIT...
Positive Results From The Phase 2 AESOP Trial Evaluating OCA For The Treatment Of...
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of...
Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017
Clinical and laboratory personnel with the need to store vaccines, pharmaceuticals and other molecular or...
Spheryx Awarded Phase II NIH SBIR Grant to Support Extension of Total Holographic Characterization
Spheryx, Inc. announced that the National Center for Advancing Translational Science (NCATS) of the NIH...
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from...
Viking Therapeutics, Inc , a clinical-stage biopharmaceutical company focused on the development of novel therapies...
Cannabics Pharmaceuticals Receives Positive Results In Drug Sensitivity Tests On CTCs
Cannabics Pharmaceuticals Inc announced it received positive results from screening necrosis (cell death) of circulating...
Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ...
Boston Biomedical Inc, announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin...
OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 For the Treatment...
OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate for...
goBalto and Informa Partner to Accelerate Site Selection for Global Clinical Trials
goBalto, Inc., the leading provider of cloud-based clinical study startup (SSU) solutions, announced its partnership...
